A narrative review of norovirus epidemiology, biology, and challenges to vaccine development

Katherine B. Carlson,Anne Dilley,Thomas O’Grady,Jordan A. Johnson,Ben Lopman,Emma Viscidi

DOI: https://doi.org/10.1038/s41541-024-00884-2

2024-05-30

npj Vaccines

Abstract:Norovirus is a leading cause of acute gastroenteritis (AGE) globally. AGE resulting from norovirus causes significant morbidity and mortality in countries of all income levels, particularly among young children and older adults. Prevention of norovirus AGE represents a unique challenge as the virus is genetically diverse with multiple genogroups and genotypes cocirculating globally and causing disease in humans. Variants of the GII.4 genotype are typically the most common genotype, and other genotypes cause varying amounts of disease year-to-year, with GII.2, GII.3, and GII.6 most prevalent in recent years. Noroviruses are primarily transmitted via the fecal-oral route and only a very small number of virions are required for infection, which makes outbreaks of norovirus extremely difficult to control when they occur. Settings like long-term care facilities, daycares, and hospitals are at high risk of outbreaks and can have very high attack rates resulting in substantial costs and disease burden. Severe cases of norovirus AGE are most common in vulnerable patient populations, such as infants, the elderly, and immunocompromised individuals, with available treatments limited to rehydration therapies and supportive care. To date, there are no FDA-approved norovirus vaccines; however, several candidates are currently in development. Given the substantial human and economic burden associated with norovirus AGE, a vaccine to prevent morbidity and mortality and protect vulnerable populations could have a significant impact on global public health.

immunology,medicine, research & experimental

What problem does this paper attempt to address?

This paper aims to address the epidemiology, biological characteristics, and challenges in vaccine development for acute gastroenteritis (AGE) caused by Norovirus.

Specifically, the paper attempts to address the following issues:

1. **Epidemiological characteristics of Norovirus**: The paper provides a detailed description of the global spread of Norovirus, including its incidence, mortality, and disease burden across different age groups. Special attention is given to vulnerable populations such as children, the elderly, and immunocompromised individuals.

2. **Biological characteristics of Norovirus**: The paper explores the genetic diversity and molecular epidemiological features of Norovirus, including the distribution and variation of different genotypes. It focuses on the high prevalence of the GII.4 genotype and its impact on disease severity.

3. **Challenges in vaccine development**: The paper analyzes the difficulties in developing a Norovirus vaccine, including the high genetic diversity of the virus, the complexity of cross-protection, and the instability of immune responses. Additionally, it discusses the progress of current vaccine candidates and future research directions.

Through these contents, the paper aims to provide comprehensive scientific evidence for the research and prevention of Norovirus, particularly to guide vaccine development.